Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. (2023)

Peer-Reviewed Study · Yu Been Shin; Ju-Yeon Choi; Dae Hwan Shin et al. · 2023

Yu Been Shin et al., 2023: Shin et al. test fenbendazole/rapamycin micelles in ovarian cancer cells and an orthotopic model, reporting a 6.9-fold potency gain over free drug and suppressed tumour growth without toxicity.

In the clonogenic assay, M-FR was 6.9 times more effective than that free fenbendazole/rapamycin.

Yu Been Shin et al., 2023: Shin et al. test fenbendazole/rapamycin micelles in ovarian cancer cells and an orthotopic model, reporting a 6.9-fold potency gain over free drug and suppressed tumour growth without toxicity. Study type: ovarian cancer cell line (HeyA8) plus an orthotopic mouse model. N: not stated in the abstract. Country: Korea (CHA University; Samsung Medical Center). Dose: micelle size 37.2 nm, fenbendazole encapsulation 75.7%; in vivo dosing in the full text. Funder: not stated in the record. Declared conflicts: 'The authors report no conflicts of interest in this work.' Comparator: free fenbendazole/rapamycin and vehicle. Study type: animal.